Bladder Cancer

Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discussed results of the KEYNOTE-052 study of pembrolizumab as a first-line therapy for patients with cisplatin-ineligible advanced urothelial cancer.

Jay D. Raman, MD, professor of Surgery and chief of the Division of Urology at Penn State Milton S. Hershey Medical Center, discusses hematuria in patients with urothelial carcinoma.

Pembrolizumab (Keytruda) has been approved by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Based on results from Maslach Burnout Inventory (MBI) questions included as part of the 2016 American Urological Association (AUA) Census, burnout rates among urologists are lower than previously reported, but the issue still remains important.

Pam Profusek, RN, MS, discusses how to manage the AEs associated with immunotherapy agents, like durvalumab.

Atezolizumab failed to meet the primary endpoint of improving overall survival in the second-line setting for patients with locally advanced or metastatic urothelial carcinoma.

An accelerated approval for the PD-L1 inhibitor avelumab (Bavencio) has been granted by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Matthew I. Milowsky, MD, discusses advances with checkpoint inhibitors in the treatment paradigm for urothelial cancer.

An overview of FDA news that happened in April.

The PD-L1 inhibitor durvalumab has been granted an accelerated approval by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Emil Christensen, PhD candidate, Aarhus University Hospital, Denmark, discusses a liquid biopsy analysis of <em>FGFR3</em> and <em>PIK3CA</em> hotspot mutations for disease surveillance in bladder cancer.

Atezolizumab (Tecentriq) has been granted an accelerated approval by the FDA as a frontline treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

The IDO1 inhibitor BMS-986205 had &quot;best-in-class&quot; activity as demonstrated by kynurenine reductions and IDO1 inhibition for patients with advanced tumors in a phase I/IIa study.

Evan Y. Yu, MD, discusses&nbsp;the current treatment options for metastatic urothelial carcinoma, the unmet needs that still exist in this space, and the possibilities for the future treatment landscape.

The PD-L1 inhibitor durvalumab demonstrated compelling clinical activity and a manageable safety profile as second-line therapy for locally advanced or metastatic urothelial cancer.

The antibody-drug conjugate sacituzumab govitecan demonstrated an overall response rate of 31% in heavily pretreated patients with metastatic urothelial cancer.

Arjun Balar, MD, discusses the treatment considerations he makes when treating patients with urothelial carcinoma, the role of PD-L1 tumor expression and immune checkpoint inhibitors, and the potential for new immunotherapy agents in this space.

As immunotherapies become a greater part of the treatment paradigm of various cancers, researchers are spending more time developing ways to determine which patients will respond better to immunotherapy. Mutational load is one such biomarker that appears to have an impact on response to immunotherapy, particularly for checkpoint inhibitors.

Immunotherapy treatments for several tumor types has been developing steadily for years. However, the options for patients with bladder cancer have been limited until quite recently.

Robert Huddart, professor, The Institute of Cancer Research, discusses the HYBRID trial which assessed&nbsp;hypofractionated bladder radiotherapy with or without image guided adaptive planning in elderly patients with bladder cancer.

The combination of the PD-1 inhibitor pembrolizumab with chemotherapy induced objective responses in one-third of patients with previously treated metastatic urothelial carcinoma.

Andrea Apolo, MD, discusses promising early data demonstrating the activity and safety of cabozantinib and nivolumab, with or without ipilimumab, in bladder cancer and other advanced genitourinary cancers.<br /> &nbsp;

A biologics license application for avelumab has been granted a priority review by the FDA for the treatment of patients with locally advanced or metastatic urothelial carcinoma.

Matthew Galsky, MD, professor of Medicine at the Mount Sinai School of Medicine, discusses results of a study examining nivolumab monotherapy in metastatic bladder cancer.

A supplemental Biologics License Application for pembrolizumab has been granted a priority review by the FDA for the treatment of patients with locally advanced or metastatic urothelial cancer who progress following platinum-containing chemotherapy.

Pembrolizumab has been granted a priority review by the FDA as a treatment for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Nivolumab has been granted an accelerated approval by the FDA as a treatment for patients with locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy, based on findings from a phase II CheckMate-275 study.

Treatment with the PD-1 inhibitor pembrolizumab significantly prolonged overall survival over investigators&rsquo; choice of chemotherapy in patients with recurrent advanced urothelial carcinoma.

A supplemental new drug application for the PD-L1 inhibitor atezolizumab has been granted priority review by the FDA in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma as a frontline therapy or following progression occurring &ge;12 months after neoadjuvant or adjuvant chemotherapy.

Geoffrey Sklar, MD,&nbsp;Chief Medical Officer, Chesapeake Urology Associates, discusses the possibility for immunotherapy as a neoadjuvant treatment in bladder cancer.